InflaRx presents kidney data: Needham upgrades InflaRx stock

Published on 10/13/2026 at 03:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Izicopan achieved at least 90.00 percent C5a blockade over 14 days. InflaRx stock has a poster scheduled for October 22, 2026 in Denver.

Key points in brief

InflaRx had announced an izicopan poster at Kidney Week on October 2, 2026, with at least 90.00 percent C5a blockade over 14 days.
Needham upgraded InflaRx from Neutral to Buy on September 14, 2026.
InflaRx held EUR 158.4 million in cash and marketable securities as of June 30, 2026, while first-half operating cash outflow was EUR 10.0 million.
The last Lang & Schwarz quote was EUR 1.43 on October 12, 2026 at 10:59 p.m. CEST.

IFRX, NL0012661870, Illustration mit AI erstellt.

InflaRx (ISIN NL0012661870) had announced on October 2, 2026, that izicopan would be presented at Kidney Week, with at least 90.00 percent C5a blockade over 14 days, according to GlobeNewswire. On September 14, 2026, MarketScreener reported that Needham had upgraded the stock from Neutral to Buy.

Kidney data set the next test

The poster is scheduled for October 22, 2026, during the American Society of Nephrology's Kidney Week in Denver. The program concerns izicopan, an oral C5a receptor inhibitor that InflaRx is developing for ANCA-associated vasculitis and additional renal diseases, according to GlobeNewswire.

The key distinction for investors is the stage of the evidence. The 90.00 percent blockade figure comes from pharmacokinetic and pharmacodynamic work, while the next development step is a planned Phase 2 program in ANCA-associated vasculitis and kidney diseases. InflaRx had described the planned start as late 2026 or early 2027 in its recent corporate materials, as reported by TickerGuard.

Cash supports the pipeline

InflaRx held EUR 158.4 million in cash and marketable securities as of June 30, 2026, while operating cash outflow was EUR 10.0 million in the first half of 2026, according to TickerGuard. The cash balance gives the company room to finance development, but the funding picture also reflects the May capital raise.

On May 6, 2026, InflaRx priced a USD 150.0 million underwritten offering, with 75.0 million new shares sold at USD 2.00 each, according to TickerGuard. Shares outstanding rose from 72.3 million at the end of 2025 to 147.4 million on June 30, 2026, creating a direct dilution counterweight to the larger cash reserve.

What comes next for InflaRx?

The next two dated milestones are the izicopan poster on October 22, 2026, and InflaRx's virtual Capital Markets Day on November 3, 2026. The latter is scheduled to center on the company's ANCA-associated vasculitis strategy, according to GlobeNewswire.

InflaRx's commercial base remains small: GOHIBIC revenue was EUR 29,331 in fiscal year 2025, against EUR 7.27 million in cost of sales, according to TickerGuard. That contrast makes the October and November milestones important valuation reference points because the investment case depends more on izicopan development than on current product revenue.

Last euro quote and trading context

The last available quote was EUR 1.43 at Lang & Schwarz on October 12, 2026 at 10:59 p.m. CEST. The quote was unchanged from EUR 1.43 in the Lang & Schwarz data set, while the Xetra reference close required for a percentage comparison was not established.

The further course of trading is shown by the continuously updated real-time quote of InflaRx stock.